Evaluating outcomes of treatments for persons with psychotic disorders

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages 61-67

  Lehman, Anthony F ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG COSTS; HEALTH CARE REFORM; HUMANS; PIRENZEPINE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029860685     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Peralta V, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1995;35:726-736
2. Carpenter WT Jr, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:681-690
3. Attkisson C, Cook J, Karno M, et al. Clinical services research. Schizophr Bull 1992;18:561-626
4. Dixon LB, Lehman AF, Levine L. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995;21:567-577
5. Diamond R. Drugs and the quality of life: the patient's point of view. J Clin Psychiatry 1985;46(5, sec 2):29-35
6. Awad AG. Drug therapy in schizophrenia: variability of outcome and prediction of response. Can J Psychiatry 1989;34:711-720
7. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41
8. Baldessarini RJ, Cohen BM, Teicher M. Pharmacologic treatment. In: Levy ST, Ninan PT, eds. Schizophrenia Treatment of Acute Episodes. Washington, DC: American Psychiatric Press; 1990:61-118
9. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, vol 5. Baltimore, Md: Williams & Wilkins; 1989:1591-1626
10. Sullivan GS, Wells KB, Leake B. Clinical factors associated with better quality of life in a seriously mentally ill population. Hosp Community Psychiatry 1992;43:794-798
11. Meltzer HY, Bymett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897
12. Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Evaluation and Program Planning 1983;6:143-151
13. Van Kammen DP, Marder SR. Dopamine receptor antagonists. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, vol 6. Baltimore, Md: Williams & Wilkins; 1995:1987-2021
14. 1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatric Annals 1996;26:88-92
15. Lehman AF, Carpenter WT, Goldman HH, et al. Treatment outcomes in schizophrenia: implications for practice, policy, and research. Schizophr Bull 1995;21:669-675
16. Schooler NR, Keith SJ, Severe JB, et al. Acute treatment response and short term outcome in schizophrenia: first results of the NIMH Treatment Strategies in Schizophrenia study. Psychopharmacol Bull 1989;25:331-335
17. Kissling W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry 1992;161(suppl 18):133-139
18. Knapp M, Beecham J. Costing mental health services. Psychol Med 1990; 20:893-908